Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Tick Bites D064927 1 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Reproductive Tract Infections D060737 1 associated lipids
Granulomatous Mastitis D058890 1 associated lipids
Trichiasis D058457 1 associated lipids
Asymptomatic Infections D058345 1 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Neglected Diseases D058069 3 associated lipids
Corneal Endothelial Cell Loss D055954 1 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Acute Lung Injury D055371 33 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Tracheobronchomalacia D055089 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Hyper-IgM Immunodeficiency Syndrome D053306 1 associated lipids
Pyomyositis D052880 2 associated lipids
Male Urogenital Diseases D052801 1 associated lipids
Tendinopathy D052256 3 associated lipids
Mucositis D052016 7 associated lipids
Pyloric Stenosis, Hypertrophic D046248 2 associated lipids
Moraxellaceae Infections D045828 3 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Communicable Diseases, Emerging D021821 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Focal Nodular Hyperplasia D020518 1 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Pouchitis D019449 3 associated lipids
Pseudolymphoma D019310 1 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Abdominal Abscess D018784 2 associated lipids
Parasitemia D018512 5 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
T-Lymphocytopenia, Idiopathic CD4-Positive D018344 1 associated lipids
Furcation Defects D017823 1 associated lipids
Granuloma, Pyogenic D017789 2 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Pelvic Pain D017699 7 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Neisseriaceae Infections D016870 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Malaria, Falciparum D016778 22 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Pneumocystis Infections D016720 1 associated lipids
Vaginosis, Bacterial D016585 10 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Helicobacter Infections D016481 21 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Erythema Chronicum Migrans D015787 3 associated lipids
Corneal Edema D015715 3 associated lipids
Frontal Sinusitis D015522 1 associated lipids
Ethmoid Sinusitis D015521 2 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Superinfection D015163 3 associated lipids
Yaws D015001 4 associated lipids
Wound Infection D014946 12 associated lipids
Whooping Cough D014917 6 associated lipids
Vomiting D014839 21 associated lipids
Vertigo D014717 4 associated lipids
Urticaria D014581 13 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Urethritis D014526 9 associated lipids
Urethral Diseases D014522 4 associated lipids
Typhus, Endemic Flea-Borne D014437 3 associated lipids
Typhoid Fever D014435 2 associated lipids
Tuberculosis, Urogenital D014401 2 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Trismus D014313 1 associated lipids
Trichomonas Infections D014245 3 associated lipids
Toxoplasmosis, Ocular D014126 2 associated lipids
Toxoplasmosis, Congenital D014125 2 associated lipids
Toxoplasmosis D014123 9 associated lipids
Tooth, Impacted D014095 9 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Erosion D014077 2 associated lipids
Tick Infestations D013984 4 associated lipids
Tenosynovitis D013717 3 associated lipids
Syphilis, Latent D013592 4 associated lipids
Syphilis D013587 6 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomach Diseases D013272 7 associated lipids
Stevens-Johnson Syndrome D013262 3 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Vranes J et al. Influence of subinhibitory concentrations of ceftazidime, ciprofloxacin and azithromycin on the morphology and adherence of P-fimbriated escherichia coli. 1996 J Chemother pmid:8873829
Laing RB et al. Clinical features, outcome and survival from cerebral toxoplasmosis in Edinburgh AIDS patients. 1996 Int J STD AIDS pmid:8876356
Berg-Candolfi M and Candolfi E Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection. 1996 Int. J. Parasitol. pmid:9024879
Tansey MJ and Moe JB Severe neutropenia and prophylactic doses of rifabutin. 1996 Lancet pmid:8950911
Sefton AM et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. 1996 J. Clin. Periodontol. pmid:8951627
Griffith DE et al. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease. 1996 Clin. Infect. Dis. pmid:8953085
Clearance to market azithromycin as prevention for a common OI in advanced AIDS. 1996 AIDS Patient Care STDS pmid:11361535
Brihmer C et al. Efficacy and safety of azithromycin versus lymecyline in the treatment of genital chlamydial infections in women. 1996 Scand. J. Infect. Dis. pmid:8953672
Prophylactic antibiotic receives speedy FDA approval to reduce MAC disease in advanced HIV. 1996 AIDS Patient Care STDS pmid:11361569
Van Bambeke F et al. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. 1996 Eur. J. Pharmacol. pmid:8957238
Azithromycin and OIs. 1996 AIDS Patient Care STDS pmid:11361699
Montenez JP et al. Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. 1996 Eur. J. Pharmacol. pmid:8957239
Prescott LM Macrolides, azalides, and streptogrammins. 1996 J Int Assoc Physicians AIDS Care pmid:11363516
Currier J Progress report: prophylaxis and therapy for MAC. 1996 AIDS Clin Care pmid:11363599
Old drug approved for MAC prevention. 1996 AIDS Alert pmid:11363659
Torres G MAC prophylaxis revisited. 1996 GMHC Treat Issues pmid:11363706
Antivirals key to MAC prevention regimen. 1996 AIDS Alert pmid:11363722
Segreti J et al. In vitro activity of macrolides against intracellular Legionella pneumophila. 1996 Diagn. Microbiol. Infect. Dis. pmid:8902407
Tabbara KF et al. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. 1996 Ophthalmology pmid:8637698
Bertoni G et al. Triple therapy with azithromycin, omeprazole, and amoxicillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. 1996 Am. J. Gastroenterol. pmid:8607489
Hulten K et al. In-vitro activity of azithromycin in against intracellular Helicobacter pylori. 1996 J. Antimicrob. Chemother. pmid:9182105
Di Mario F et al. Azithromycin for the cure of Helicobacter pylori infection. 1996 Am. J. Gastroenterol. pmid:8607490
Na-Bangchang K et al. Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria. 1996 Southeast Asian J. Trop. Med. Public Health pmid:9185262
Wittner M et al. Atovaquone in the treatment of Babesia microti infections in hamsters. 1996 Am. J. Trop. Med. Hyg. pmid:8780464
Apseloff G et al. Severe neutropenia caused by recommended prophylactic doses of rifabutin. 1996 Lancet pmid:8782773
ZaÄ­tseva EA et al. [Comparative study of the antimicrobial activity of pefloxacin, ciprofloxacin, norfloxacin and azithromycin with respect to Strains of Yersinia pseudotuberculosis]. 1996 Antibiot. Khimioter. pmid:8762820
Montero L A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and/or soft tissue infections. 1996 J. Antimicrob. Chemother. pmid:8818853
Nahata M Drug interactions with azithromycin and the macrolides: an overview. 1996 J. Antimicrob. Chemother. pmid:8818854
Treadway G and Pontani D Paediatric safety of azithromycin: worldwide experience. 1996 J. Antimicrob. Chemother. pmid:8818855
Carbon C et al. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. 1996 J. Antimicrob. Chemother. pmid:8818856
Gerbaux C et al. Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. 1996 FEBS Lett. pmid:8830663
Domingo S and Gamazo C Inadequate azithromycin activity against Brucella melitensis in mice with acute or chronic infections. 1996 J Chemother pmid:8835110
Conte JE et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. 1996 Antimicrob. Agents Chemother. pmid:8807050
Nash KA and Inderlied CB Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. 1996 Antimicrob. Agents Chemother. pmid:8807078
Dupont C et al. Microbiological findings about pulmonary cryptosporidiosis in two AIDS patients. 1996 J. Clin. Microbiol. pmid:8748314
Wildfeuer A et al. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. 1996 Antimicrob. Agents Chemother. pmid:8787883
Jackson MA et al. Breakthrough sepsis in macrolide-resistant pneumococcal infection. 1996 Pediatr. Infect. Dis. J. pmid:8933560
Hicks P et al. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. 1996 J. Pediatr. pmid:8765631
Boran M et al. Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. 1996 Transplant. Proc. pmid:8769234
Luft BJ et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. 1996 Ann. Intern. Med. pmid:8610947
Wintermeyer SM et al. Dirithromycin: a new macrolide. 1996 Ann Pharmacother pmid:8893122
Ridgway GL Azithromycin in sexually transmitted diseases. 1996 Int J STD AIDS pmid:8652719
Akita H et al. [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8986553
Nishimura T et al. [Clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986554
Young LS Azithromycin in the management of opportunistic infections. 1996 Int J STD AIDS pmid:8652721
Haruta T and Kobayashi Y [Therapeutic efficacy of azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8986555
Chang HR The potential role of azithromycin in the treatment of prophylaxis of toxoplasmosis. 1996 Int J STD AIDS pmid:8652722
Kuroda Y and Ito M [Therapy with azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8986556
Okamoto T and Sekiguchi T [Clinical studies on azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8986557
Toyonaga Y et al. [Pharmacokinetic and clinical evaluation of azithromycin using fine granules or capsules in the pediatric patients]. 1996 Jpn J Antibiot pmid:8988410
Okumura A and Kuno K [Pharmacokinetic and clinical evaluation of azithromycin in pediatrics]. 1996 Jpn J Antibiot pmid:8988411
Kobayashi Y et al. [Clinical study of a macrolide antibiotic, azithromycin, in pediatric patients]. 1996 Jpn J Antibiot pmid:8988412
Furukawa S and Okada T [A clinical evaluation of azithromycin in the treatment of pediatric infection]. 1996 Jpn J Antibiot pmid:8988413
Okada T et al. [Pharmacokinetic and clinical evaluations of azithromycin in the pediatric field]. 1996 Jpn J Antibiot pmid:8988414
Ishida Y et al. [Pharmacokinetic and clinical evaluation of azithromycin in pediatric infections]. 1996 Jpn J Antibiot pmid:8988415
Ohtsuka Y et al. [Pharmacokinetic and clinical studies on azithromycin in children]. 1996 Jpn J Antibiot pmid:8988416
Murphy GS et al. Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. 1996 Clin. Infect. Dis. pmid:8722958
Scorneaux B et al. Effect of recombinant human gamma interferon on intracellular activities of antibiotics against Listeria monocytogenes in the human macrophage cell line THP-1. 1996 Antimicrob. Agents Chemother. pmid:8723471
Havlir DV et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. 1996 N. Engl. J. Med. pmid:8676932
Tursi A et al. The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection. 1996 Am. J. Gastroenterol. pmid:8677967
Thorpe EM et al. Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. 1996 Genitourin Med pmid:8698374
Wilton LV et al. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. 1996 Br J Clin Pharmacol pmid:8730972
Bedos JP and Veber B [Lower respiratory infections: predictive factors of therapeutic response]. 1996 Rev Pneumol Clin pmid:9033917
Zuck P [Efficacy of a 5-day treatment with an azalide (azithromycin) in superinfections of chronic bronchitis]. 1996 Rev Pneumol Clin pmid:9033919
Hayle R et al. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8997555
Adhikari P et al. Evaluation of safety and efficacy of azithromycin in lower respiratory tract infections (LRTI) 1996 Indian J Med Sci pmid:9057364
Thylefors B Trachoma--new opportunities to tackle an old problem. 1996 Br J Ophthalmol pmid:9059262
Cammarota G et al. Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. 1996 Aliment. Pharmacol. Ther. pmid:8971300
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Andenaes K et al. Preoperative bacterial colonization and its influence on postoperative wound infections in plastic surgery. 1996 J. Hosp. Infect. pmid:8971618
Three new studies expand understanding of MAC therapy. 1996 Am J Health Syst Pharm pmid:8899122
Evans LA et al. Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model. 1996 Pharm. Res. pmid:8899856
O'Doherty B Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Paediatric Azithromycin Study Group. 1996 Eur. J. Clin. Microbiol. Infect. Dis. pmid:8922571
Griffith DE et al. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. 1996 Clin. Infect. Dis. pmid:8922790
Chulig I [Pharmacokinetic profile of azithromycin. Role in the treatment of genital Chlamydia infections]. 1996 Antibiot. Khimioter. pmid:8929112
Kuznetsova SM ["Sumamed in the treatment of urogenital infections"]. 1996 Antibiot. Khimioter. pmid:8929115
Skripkin IuK et al. [The problem of diagnosis and treatment of urogenital chlamydiosis in Russia]. 1996 Antibiot. Khimioter. pmid:8929120
Vasil'ev MM and Gazarian IIu [Clinico-laboratory evaluation of the effectiveness of azithromycin in the treatment of patients with Chlamydia and mixed Chlamydia-gonorrhea infections]. 1996 Antibiot. Khimioter. pmid:8929122
Schaad UB and Heynen G Evaluation of the efficacy, safety and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study. The Swiss Tonsillopharyngitis Study Group. 1996 Pediatr. Infect. Dis. J. pmid:8878223
Cellesi C et al. Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. 1996 J Chemother pmid:8808714
Welsh L et al. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8787907
Mein J et al. Donovanosis: sequelae of severe disease and successful azithromycin treatment. 1996 Int J STD AIDS pmid:8940677
Hoque S et al. Rhodococcus equi in CAPD-associated peritonitis treated with azithromycin. 1996 Nephrol. Dial. Transplant. pmid:8941608
Wiselka MJ et al. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. 1996 J. Infect. pmid:8945715
Gómez E et al. Interaction between azithromycin and cyclosporin? 1996 Nephron pmid:8856287
Delmée M et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxycillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin, and azithromycin. 1996 Acta Clin Belg pmid:8858889
Watt B et al. Comparative activity of azithromycin against clinical isolates of mycobacteria. 1996 J. Antimicrob. Chemother. pmid:8889727
Mashkilleyson AL et al. Treatment of syphilis with azithromycin. 1996 Int J STD AIDS pmid:8652720
Patel KB et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1996 Antimicrob. Agents Chemother. pmid:8891147
Bauernfeind A et al. Comparative pharmacodynamics of clarithromycin and azithromycin against respiratory pathogens. 1995 Sep-Oct Infection pmid:8557398
Erdogru T et al. The treatment of non-gonococcal urethritis with single dose oral azithromycin. 1995 Sep-Oct J. Int. Med. Res. pmid:8529783
Haddix AC et al. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women. 1995 Sep-Oct Sex Transm Dis pmid:7502180
Sternon J et al. Azithromycin compared with clarithromycin in the treatment of adult patients with acute purulent tracheobronchitis: a cost of illness study. 1995 Nov-Dec J. Int. Med. Res. pmid:8746608
Höffler D et al. Pharmacokinetics of azithromycin in normal and impaired renal function. 1995 Nov-Dec Infection pmid:8655206
Hashisaki GT Update on macrolide antibiotics. 1995 May-Jun Am J Otolaryngol pmid:7661309
What's in the water? 1995 Mar-Apr Treat Rev pmid:11362299
Rifabutin for MAC questioned. 1995 Jul-Aug Posit Aware pmid:11362571
Amin NM and Breadon G An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. 1995 Jul-Aug Clin Ther pmid:8565033
Qadri SM et al. Antibacterial activity of azithromycin against Brucella melitensis. 1995 Jul-Aug Chemotherapy pmid:7555205
Nuovo J et al. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis. 1995 Jan-Feb J Am Board Fam Pract pmid:7701965